1. <optgroup id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></optgroup>
    <cite id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></cite>
      1. <legend id="wrmvh"></legend>

        <ol id="wrmvh"></ol>

          1. <strong id="wrmvh"></strong>
          2. <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <optgroup id="wrmvh"></optgroup>
            <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <span id="wrmvh"><sup id="wrmvh"><object id="wrmvh"></object></sup></span>
            1. <span id="wrmvh"><video id="wrmvh"></video></span>
              <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
              <strong id="wrmvh"></strong>
              <legend id="wrmvh"><i id="wrmvh"></i></legend>
              1. <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
                1.  
                   
                   
                   
                   
                  臨床PI
                  孟志強 教授
                  教授,博士生導師
                  E-mail: mengzhq@yeah.net
                   

                    1999年畢業于上海醫科大學獲得博士學位。2004年在美國M.D. Anderson腫瘤中心學習。現任復旦大學附屬腫瘤醫院微創治療中心/中西醫結合科主任、美國M.D. Anderson腫瘤中心兼職教授、中國臨床腫瘤學會腫瘤消融治療專家委員會主任委員、上海市抗癌協會腫瘤微創治療委員會主任委員、中國醫師協會微無創醫學專業委員會副主任委員、國際肝膽胰協會中國分會介入治療專業委員會副主任委員、上海市中西醫結合學會胰腺病專業委員會副主任委員、上海中西醫結合學會肝病專業委員會副主任委員、上海市抗癌協會理事、亞洲腫瘤消融學會理事、國際微無創醫學協會理事、《JCRT》副主編、《腫瘤》雜志編委等職。

                    2011年獲得上海市科技進步二等獎和教育部科技進步二等獎;2012年獲得中西醫結合學會一等獎;2012年獲得明治生命科學獎;2016年獲得上海市科技進步一等獎。入選上海市“領軍人才計劃”、“百人計劃”。作為項目負責人主持美國NIH/NCI-R01、U19項目、國家自然科學基金重點項目、上海市科委重點項目等10余項,資助金額超過2000萬。先后在Gastroenterology、Oncogene、Mol Oncol、Brit J Cancer、Eur J Cancer、Autophage等發表論文163篇,他引超過2200次,H-index:27。批準專利2項。主持臨床研究40余項。


                  研究領域:

                    肝、膽、胰腺腫瘤的耐藥機制及微創治療對策研究
                    1. Na+K+ATP酶在肝癌的功能研究及藥物篩選;
                    2. 炎性微環境與肝胰腺腫瘤腫瘤的耐藥機制;
                    3. 腫瘤微創治療的臨床研究。


                  代表性論著:

                  1. Yang LN, Ning ZY, Wang L, Yan X, Meng Z*. HSF2 regulates aerobic glycolysis by suppression of FBP1 in hepatocellular carcinoma. Am J Cancer Res, 2019 Aug 1; 9(8):1607-1621.
                  2. Shi W, Zhang C, Ning Z, Hua Y, Li Y, Chen L, Liu L, Chen Z, Meng Z*. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. J Exp Clin Cancer Res. 2019 Feb 6; 38(1):60.
                  3. Ning Z, Xie J, Chen Q, Zhang C, Xu L, Song L, Meng Z*. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther, 2019 Feb 1; 12:1021-1029.
                  4. Zhuang L, Yan X, Meng Z. Second primary malignancy in patients with cholangiocarcinoma: a population-based study. Cancer Manag Res, 2019 Mar 1; 11:1969-1983.
                  5. Jing X, Yan Z X, Ming L L, Meng Z*. Solute carrier transporters: potential targets for digestive system neoplasms. Cancer Management and Research, 2018; 10:153-166.
                  6. Wang H, Zhang C, Chi H, Meng Z*. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. Int J Oncol, 2018 Apr 2.
                  7. Wang, Q., Qu, C., Xie, F., Chen, L., Liu, L., Liang, X., Meng, Z*. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. American Journal of Cancer Research, 2017; 7(1):125-133.
                  8. Milbury, K, Kavanagh, A, Meng, Z*, Chen, Z, Chandwani, KD, Garcia, K, Perkins, GH, McQuade, J, Raghuram, NV, Nagarathna, R, Liao, Z, Nagendra, HR, Chen, J, Guo, X, Liu, L, Arun, B & Cohen, L. Depressive symptoms and positive affect in Chinese and United States breast cancer survivors: a cross-cultural comparison. Supportive Care in Cancer, 2017 Jul; 25(7):2103-2109.
                  9. Xie, J, Chen, LH, Ning, ZY, Zhang, CY, Chen, H, Chen, Z, Meng, Z*, Zhu, XY. Effect of transcutaneous electrical acupoint stimulation combined with palonosetron on chemotherapy-induced nausea and vomiting: A single-blind, randomized, controlled trial. Chinese Journal of Cancer, 2017 Jan 10; 36(1):6.
                  10. Zhang, C., Wang, H., Ning, Z., Xu, L., Zhuang, L., Wang, P., & Meng, Z. Q*. Hyperfibrinogen is associated with the systemic inflammatory response and predicts poor prognosis in intrahepatic cholangiocarcinoma. International Journal of Clinical and Experimental Medicine, 2017; 10(3): 5670-5677.
                  11. Liu, F, Meng, Z*, Shao, G, Wang, J, Wang, Z, Yang, J, Yip, CSM & He, D. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Molecular Biology Reports, 2017; 44(1):149-158.
                  12. Zhang C, Wang H, Ning Z, Xu L, Zhuang L, Wang P, Meng Z*. Serum liver enzymes serve as prognostic factors in patients with intrahepatic cholangiocarcinoma. Onco Targets Ther, 2017 Mar 6; 10: 1441-1449.
                  13. Ning, ZY, Cheng, CS, Xie, J, Chen, QW, Xu, LT, Zhuang, L, Zhang, CY, Song, LB, Shi, WD, Zhu, XY, Wang, P, Wang, K, Meng, ZQ*. A retrospective analysis of survival factors of High Intensity Focused Ultrasound (HIFU) treatment for unresectable pancreatic cancer. Discovery Medicine, 2016 Jun; 21(118):435-45.
                  14. Wang, H, Ning, Z, Li, Y, Zhu, X, Meng Z*. Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via hedgehog signaling. Molecular Medicine Reports, 2016; 14(3):1907-1914
                  15. Wang H, Zhang C, Ning Z, Xu L, Zhu X, Meng Z*. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. Int J Oncol, 2016 Mar; 48(3):1229-41.
                  16. Zhuang L, Xu L, Wang P, Jiang Y, Yong P, Zhang C, Zhang H, Meng Z*, Yang P. Na+/K+-ATPase 1 subunit, a novel therapeutic target for hepatocellular carcinoma. Oncotarget, 2015; 6(29):28183-93.
                  17. Shen Y, Pan Y, Xu L, Chen L, Liu L, Chen H, Chen Z, Meng Z*. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Tumour Biol, 2015; 36(6):4525-34.
                  18. Wang SY, Feng LY, Meng ZQ*. Bicluster and pathway enrichment analysis related to tumor progression of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 2015; 19(7):1191-7.
                  19. Zhuang LP, Meng ZQ*. Serum miR-224 reflects stage of hepatocellular carcinoma and predicts survival. Biomed Res Int, 2015; 2015:731781.
                  20. Zhuang L, Xu L, Wang P, Meng Z*. Serum miR-128-2 serves as a prognostic marker for patients with hepatocellular carcinoma. PLoS One, 2015 Feb 2; 10(2):e0117274.
                  21. Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng ZQ*. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene, 2014; 33(4):514-24.
                  22. Shi W, Yin J, Chen Z, Chen H, Liu L, Meng Z*. Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27. Tumour Biol, 2014 Nov; 35(11):11147-51.
                  23. Wang H, Xu L, Zhu X, Wang P, Chi H, Meng ZQ*. Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. Oncol Rep, 2014; 32(4):1465-72.
                  24. Chen QW, Cheng CS, Chen H, Ning ZY, Tang SF, Zhang X, Zhu XY, Vargulick S, Shen YH, Hua YQ, Xie J, Shi WD, Gao HF, Xu LT, Feng LY, Lin JH, Chen Z, Liu LM, Ping B, Meng ZQ*. Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤200 ng/ml--a study based on 4,312 patients. PLoS One, 2014; 9(8):e101536.
                  25. Chen QW, Chen H, Cheng JS, Meng ZQ*. MDM2 SNP309T>G polymorphism and hepatocellular carcinoma risk: a meta-analysis. Tumour Biol, 2014; 35(5):4147-51.
                  26. Chen QW, Zhu XY1, Li YY2, Meng ZQ*. Epigenetic regulation and cancer (review). Oncol Rep, 2014; 31(2):523-32.
                  27. Wang P, Zhang J, Zhang L, Zhu Z, Fan J, Chen L, Zhuang L, Luo J, Chen H, Liu L, Chen Z, Meng Z*. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Gastroenterology, 2013; 145(5):1133-1143.e12.
                  28. Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z*. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol, 2013; 7(3):334-45.
                  29. Wang P, Zhang L, Chen Z, Meng Z*. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Autophagy, 2013; 9(12):2171-2.
                  30. Chen Q, Zhu X, Chen Q, Wang K, Meng ZQ*. Unresectable giant pancreatic neuroendocrine tumor effectively treated by high-intensity focused ultrasound: a case report and review of the literature. Pancreatology, 2013; 13(6):634-8.
                  31. Xie J, Chen Z, Liu L, Li P, Zhu X, Gao H, Meng Z*. shRNA-mediated Slc38a1 silencing inhibits migration, but not invasiveness of human pancreatic cancer cells. Chin J Cancer Res, 2013; 25(5):514-9.
                  32. Zhuang L, Zeng X, Yang Z, Meng Z*. Effect and safety of interferon for hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One, 2013; 8(9):e61361.
                  33. Wang S, Zhuang L, Meng Z*. Hepatocellular Carcinoma More Than 3?cm in Diameter: A Systematic Review of Transcatheter Arterial Chemoembolization Plus Percutaneous Ethanol Injection versus Transcatheter Arterial Chemoembolization Alone. ISRN Gastroenterol, 2013; 2013:526024.
                  34. Wang K, Zhu H, Meng Z*, Chen Z, Lin J, Shen Y, Gao H. Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. Onkologie, 2013; 36(3):88-92.
                  35. Zhuang L, Yang Z, Zeng X, Zhua X, Chen Z, Liu L, Meng Z*. The preventive and therapeutic effect of acupuncture for radiation-induced xerostomia in patients with head and neck cancer: a systematic review. Integr Cancer Ther, 2013; 12(3):197-205.
                  36. Gao HF, Wang K, Meng ZQ*, Chen Z, Lin JH, Zhou ZH, Wang P, Shi WD, Sheng YH. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology, 2013; 60(128):1906-10.
                  37. Meng Z*, Garrett CR,Shen Y,Liu L, Yang P, Huo Y, Zhao Q, Spelman AR, Ng CS, Chang DZ, Cohen L . Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer, 2012; 107(3):411-6.
                  38. Meng Z*, Kay Garcia M, Hu C, Chiang J, Chambers M, Rosenthal DI, Peng H, Wu C, Zhao Q, Zhao G, Liu L, Spelman A, Lynn Palmer J, Wei Q, Cohen L. Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Eur J Cancer, 2012; 48(11):1692-9.
                  39. Meng Z*, Garcia MK, Hu C, Chiang J, Chambers M, Rosenthal DI, Peng H, Zhang Y, Zhao Q, Zhao G, Liu L, Spelman A, Palmer JL, Wei Q, Cohen L. Randomized controlled trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma. Cancer, 2012; 118(13):3337-44.
                  40. Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen L, Yang PY, Gu K, Meng ZQ*. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Mol Biol Rep, 2012; 39(2):1683-9.
                   
                  復旦大學腫瘤研究所 通訊地址: 東安路270號2號樓1312室 64175590-5312 Email:fuci2012@126.com
                  Copyright 2013 shca.org.cn All rights reserved. 復旦大學腫瘤研究所 版權所有
                  小草在线观看视频播放免费 含羞草研究院网站在线视频| 快看影院播放器| 20 14a天堂网在线| 24999视频| 免费 美女视频 app| 嫩草的香味z| 视频啪啪免费观看| 天天影院| 99久久就热视频精品98风险| 百度千人斩官网| 久久机热在线视频精品|